REG - Cambridge Cognition - Launch of brain health study with Oura

Cambridge Cognition HoldingsAnnouncement

Yesterday 13:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260528:nRSb1027Ga&default-theme=true

RNS Number : 1027G  Cambridge Cognition Holdings PLC  28 May 2026

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition and Oura launch large-scale brain health study integrating
cognition with wearable sleep and physiological data

 

Cambridge, UK, 28 May 2026: Cambridge Cognition Holdings plc (AIM: COG), the
neuroscience technology company whose digital cognitive assessments drive
scientific discovery, accelerate drug development and improve patient care,
announces a collaboration with ŌURA, maker of the world's leading smart ring,
on a new institutional review board (IRB)-approved brain health study.
Conducted through Oura Labs, an experimental innovation platform within the
Oura App, the study pairs Cambridge Cognition's scientifically validated
digital cognitive assessments with Oura's continuous physiological data.
Rather than focusing only on diagnosed disease, this work explores how
everyday patterns in rest, stress, and behaviour may relate to cognitive
function and performance over time.

 

Oura has established one of the world's leading consumer health platforms,
with sensing technology spanning sleep, activity, stress, cardiovascular and
metabolic health and more, alongside partnerships with more than 1,200 leading
organisations across health, wellness, and commercial brands.

 

Cambridge Cognition's scientifically validated digital cognitive assessments
from CANTAB Pathway™ have been integrated into the Oura platform as short
in-app tasks, specifically CANTAB One and CANTAB Insight. As part of this
large-scale remote observational research programme running through 2026, up
to 45,000 participating Oura members will complete these brief assessments
alongside continuous monitoring of their sleep, activity, stress and
physiological measurements captured by Oura Ring.

 

The study is intended to explore relationships between behavioural, biometric
and cognitive measures over time, helping advance understanding of how factors
such as sleep, recovery and activity may influence brain health and cognition.
The programme is also designed to assess user engagement with
consumer-integrated cognitive assessments alongside wearable-derived and
self-reported health data. Insights generated from these combined datasets are
expected to help inform future product development and scalable brain health
applications.

 

The collaboration builds on the recent expansion of CANTAB Pathway™ across
healthcare and consumer markets and reflects Cambridge Cognition's strategy of
making its cognitive assessments more accessible through scalable digital
platforms. Building on previous programmes including Project Intuition, a
23,000-participant remote cognitive assessment study conducted with Biogen and
Apple, this demonstrates the Company's ability to deploy validated cognitive
measurement at scale and generate rich longitudinal insight into cognitive
function.

 

Rob Baker, CEO, Cambridge Cognition said, "Oura combines strong scientific
credibility with significant consumer reach, making them an ideal partner on
this study as we seek to expand CANTAB Pathway™ into broader healthcare and
consumer applications. Bringing together trusted cognitive science with
wearable-derived physiological data is a powerful way to support scalable
approaches to brain health measurement, and to extend the reach of our
technology beyond traditional clinical and research environments."

"Cognitive health is one of the least understood frontiers in preventive
medicine," said Shyamal Patel, Ph.D., Senior Vice President of Science at
Oura. "By pairing validated cognitive assessments with continuous sleep,
activity, and physiological sensing, this Brain Health Study allows us to
rigorously explore how everyday biometrics and behaviors relate to cognitive
performance over time, laying a scientific foundation for future tools that
can help people understand and support their long-term brain health."

 

INVESTOR PRESENTATIONS

A pre-recorded presentation on the announcement is available to view through
Investor Meet Company:
https://www.investormeetcompany.com/companies/cambridge-cognition-holdings-plc/updates
(https://www.investormeetcompany.com/companies/cambridge-cognition-holdings-plc/updates)
.

 

ENQUIRIES

 Cambridge Cognition Holdings plc                            Tel: 01223 810700

 Rob Baker, Chief Executive Officer                          press@camcog.com (mailto:press@camcog.com)

 Ronald Openshaw, Chief Financial Officer

 Cavendish Capital Markets Limited (NOMAD and Joint Broker)  Tel: 020 7220 0500

 Geoff Nash / Elysia Bough / Joe Smith

 Harriet Ward                                                Corporate Finance

 Nigel Birks                                                 Corporate Broking

                                                             LS Specialist Sales
 Singer Capital Markets Limited (Joint Broker)                Tel: 020 7496 3000

 Amber Higgs / James Serjeant / Daniel Ingram

 

The information contained within this announcement is deemed to constitute
inside information as stipulated under the retained EU law version of the
Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK
law by virtue of the European Union (Withdrawal) Act 2018. The information is
disclosed in accordance with the Company's obligations under Article 17 of the
UK MAR. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

NOTES TO EDITORS

 

ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY™

Cambridge Cognition is a neuroscience technology company whose digital
cognitive assessments support scientific discovery, accelerate drug
development and improve patient care.

The Company has developed a suite of touchscreen and voice-based cognitive
assessments delivered under the CANTAB and Winterlight brands.  These
assessments are designed to:

·    require minimal specialist administration

·    deliver objective results in real time or shortly after completion

·    reduce administrator bias

·    support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers
in home-use settings and healthcare professionals in clinical or research
environments.

CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive
assessment solution, structured as an escalating series of tasks for use in
consumer and healthcare settings:

·    CANTAB One - a brief assessment of overall cognitive function

·    CANTAB Insight™ - a three-task battery providing deeper insight
across five cognitive sub-domains

·    CANTAB Plus - specialist disease-specific modules for use by
appropriately qualified healthcare professionals, covering eight indications
including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease,
schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

About ŌURA

ŌURA delivers personalized health data, insights, and daily guidance with
Oura Ring, the leading smart ring that helps you live healthier, longer.
Guided by a mission to shift healthcare from sick care to prevention, ŌURA
supports millions of members worldwide across sleep, activity, stress,
readiness, women's health, and heart health. Scientifically validated against
medical gold standards, the lightweight Oura Ring tracks 50+ health metrics
continuously, empowering both individuals and thousands of research teams,
healthcare providers, and organizations. With 1,000 ecosystem partners across
wellness and medicine, ŌURA is advancing the future of preventative health.
Learn more at ouraring.com
(https://www.google.com/url?q=http://ouraring.com&sa=D&source=docs&ust=1779586715774811&usg=AOvVaw1I3gRftXWY4Wo2Okw7amff)
 or connect with ŌURA on Instagram, LinkedIn, and TikTok.

Oura Ring is not a medical device and is not intended to diagnose, treat,
cure, monitor, or prevent medical conditions or illnesses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZGZKZRDGVZM



            Copyright 2019 Regulatory News Service, all rights reserved